72065622RFA00006: USAID Fighting Malaria with Social and Behavioral Change (FMSBC) program in Mozambique
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Mozambique USAID-Maputo notices from 2022.
Mozambique USAID-Maputo offered grants of up to $17.0 million (at least $17.0 million) to any type of organization. It expected to make one award worth $17.0 million in total. Applications closed on April 21, 2022.
From the official notice on Grants.gov, last changed March 21, 2022. Checked November 7, 2026.
- Award ceiling$17.0 million
- Award floor$17.0 million
- Total funding$17.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 7, 2022 |
|---|---|
| Deadline | April 21, 2022 |
| Archived by Grants.gov | May 21, 2022 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $17.0 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
USAID Fighting Malaria with Social and Behavioral Change (FMSBC) program in Mozambique The U.S. Agency for International Development (USAID)/Mozambique intends to award a five-year Cooperative Agreement (hereafter referred to as “the activity”) of up to $17 million. The purpose of the activity is to increase adoption and maintenance of malaria prevention and treatment behaviors in target areas of Mozambique through the use of evidence-based and theory-driven social and behavior change (SBC) activities. This will be achieved through the following objective: Increased and improved malaria social and behavioral change (SBC) design, implementation, and monitoring by Ministry of Health and implementation partners. These objectives will be achieved in coordination and collaboration with key partners and stakeholders, including the Government of Mozambique, other donors, implementing partners, and non-governmental organizations, and will contribute to the Ministry of Health's 2017-2022 National Malaria Control Program (NMCP) objective of implementing an effective SBC approach to ensure that people seek appropriate and timely healthcare and use an appropriate protection method. Accomplishment of these objectives will also depend on a close working relationship between this activity and other USAID activities targeting malaria control and elimination. Given the geographic scope of USAID’s malaria programming in Mozambique, activities in these areas will be implemented at the provincial, district, and community levels in provinces of Nampula, Zambezia, and Manica, in addition to providing support at the central level. This activity will also support media interventions in Cabo Delgado. USAID’s contributions in each province will be coordinated with other USAID-funded initiatives. Nampula and Zambézia continue as key provinces for USAID’s goal of reducing malaria in high transmission areas. The province of Manica is a new priority province for USAID due to its high malaria prevalence and incidence.
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 72065622RFA00006 still open?
No. It closed on April 21, 2022.
Who can apply for USAID Fighting Malaria with Social and Behavioral Change (FMSBC) program in Mozambique?
Mozambique USAID-Maputo accepted applications from any type of organization.
What is the deadline for USAID Fighting Malaria with Social and Behavioral Change (FMSBC) program in Mozambique?
Closed April 21, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $17.0 million each. About $17.0 million in total for one award.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)